5-氯-1-(萘-1-基甲氧基甲基)嘧啶-2-酮 | 88045-87-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 5-氯-1-(萘-1-基甲氧基甲基)嘧啶-2-酮
• 英文名称: 5-chloro-1-(1-naphthylmethyloxy)methyl-2(1H)-pyrimidinone
• 英文别名: 1-(1-Naphthylmethyloxy)methyl-5-chloropyrimidin-2-one；5-Chloro-1-{[(naphthalen-1-yl)methoxy]methyl}pyrimidin-2(1H)-one；5-chloro-1-(naphthalen-1-ylmethoxymethyl)pyrimidin-2-one
• CAS: 88045-87-8
• 化学式: C₁₆H₁₃ClN₂O₂
• 分子量: 300.744
• InChiKey: ZPSPWRBQISMDBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  41.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-萘甲醇 在 磺酰氯 、 sodium hydride 、 三乙胺 、 sodium iodide 作用下， 以 二氯甲烷 为溶剂， 反应 31.0h， 生成 5-氯-1-(萘-1-基甲氧基甲基)嘧啶-2-酮
  参考文献：
  名称：

  Pyrimidinones as reversible metaphase arresting agents

  摘要：

  5-Halo-N(1)-substituted 2(1H)-pyrimidinones have the ability to cause reversible arrest of mitosis during metaphase, Highly active compounds have a heteroatom (O, S or N) in the beta-position of the N(1)-carbon chain which is further substituted by an aryl group. In vitro data have been provided. It is suggested that reversible metaphase inhibitors can be used as synchronizing agents of cell-cycles by applying them in a sequential manner when a phase-specific cytotoxic drug is used in the treatment of diseases caused by uncontrolled rapidly proliferating cells. The active compounds are prepared from 2-pyrimidinones by alkylation reactions. The key reactants are alpha-chloroalkyl ethers, sulfides and amides; methods for their syntheses have been described.

  DOI：

  10.1016/0223-5234(93)90014-6

文献信息

• Substituted pyrimidin-2-ones and the salts thereof
  申请人：Nyegaard & Co. A/S

  公开号：US04539324A1

  公开（公告）日：1985-09-03

  Compounds of the general formula: ##STR1## wherein X represents halogen or trifluoromethyl; R.sup.1 and R.sup.2, independently represent hydrogen or lower alkyl; R.sup.3, R.sup.4 and R.sup.5, which may be the same or different, each represent hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower alkenoyl, C.sub.7-16 aralkyl or C.sub.6-10 aryl or a 5-9 membered unsaturated or aromatic heterocyclic ring; one or both of R.sup.4 and R.sup.5 may also represent aroyl groups; Z represents an oxygen atom or a sulfur atom or oxide thereof or a group NR.sup.6 (wherein R.sup.6 is as defined for R hereinafter or represents the group COR.sup.7 in which R.sup.7 represents hydrogen or optionally substituted aryl, heterocyclic, aralkyl, lower alkyl or lower alkoxy group; and R represents a C.sub.6-10 carbocyclic aromatic group or a heterocyclic group containing a 5-9 membered unsaturated or aromatic heterocyclic ring which ring contains one or more heteroatoms selected from O, N and S and optionally carries a fused ring which carbocyclic or heterocyclic group may carry one or more C.sub.1-4 alkyl or phenyl groups said groups being optionally substituted; and where acid or basic groups are present, the salts thereof are useful in combating abnormal cell proliferation. The compounds of the invention are prepared by inter alia alkylation, ring closure and oxidation.

  通式化合物：##STR1## 其中 X 代表卤素或三氟甲基；R.sup.1 和 R.sup.2，独立地代表氢或较低的烷基；R.sup.3、R.sup.4 和 R.sup.5，可以相同也可以不同，每个代表氢、较低的烷基、较低的烯基、较低的炔基、较低的烷酰基、较低的烯酰基、C.sub.7-16 芳基烷基或 C.sub.6-10 芳基或一个 5-9 成员的不饱和或芳香杂环；R.sup.4 和 R.sup.5 中的一个或两个也可以代表芳酰基；Z 代表氧原子或硫原子或其氧化物或一个基团 NR.sup.6（其中 R.sup.6 如下文中对 R 定义或代表基团 COR.sup.7，其中 R.sup.7 代表氢或可选择取代的芳基、杂环、芳基烷基、较低的烷基或较低的烷氧基；R 代表 C.sub.6-10 碳环芳基或含有 5-9 成员不饱和或芳香杂环的杂环基，该环包含一个或多个来自 O、N 和 S 的杂原子，并且可选择携带一个融合环，该碳环芳基或杂环基可携带一个或多个 C.sub.1-4 烷基或苯基，所述基团可选择取代；当存在酸性或碱性基团时，其盐在对抗异常细胞增殖方面是有用的。本发明的化合物通过烷基化、环闭合和氧化等方法制备。
• Pyrimidinone derivatives
  申请人：NYCOMED AS

  公开号：EP0160573A2

  公开（公告）日：1985-11-06

  Bisulphite adducts of compounds of formula (wherein R represents a group R2-CH-X-(CR4R5)nR3; R' represents a halogen atom or a trifluoromethyl group; R2 represents a hydrogen atom or a C1-4 alkyl, C1-4 alkanoyl or phenyl group; X represents an oxygen or a sulphur atom or a group , where R6 represents a formyl, C1-4 alkanoyl or C1-4 alkoxycarbonyl group; R3 represents a C6-10 carbocyclic aromatic group or a heterocyclic group containing a 5- or 6- membered unsaturated heterocyclic ring which ring contains one or more heteroatoms selected from 0, N and S and optionally carries a fused carbocyclic ring, which carbocyclic or heterocyclic group may carry one or more substituents selected from halogen atoms, C1-4 alkyl, C1-4 alkanoyl, C1-4 alkoxy, C1-4 alkoxycarbonyl, C1-4 alkylthio, hydroxyl, nitro, cyano and formyl groups, -NR7R8 groups (where R is a hydrogen atom or a C1-4 alkyl group, and RB is a hydrogen atom or a C1-4 alkyl, C1-4 alkanoyl or aroyl group) and C1-4 alkyl groups substituted by one or more hydroxy or -NR7R8 groups and halogen atoms; n is an integer having the value 0 or 1; and R4 and R5, which may be the same or different, each is a hydrogen atom or a C1-6 alkyl group) and salts of such adducts have metaphase arrest abilities and desirably good water solubilities and may be useful in combatting abnormal cell proliferation.

  式化合物的亚硫酸氢盐加合物 (其中 R 代表基团 R2-CH-X-(CR4R5)nR3； R' 代表卤素原子或三氟甲基； R2 代表氢原子或 C1-4 烷基、C1-4 烷酰基或苯基； X 代表氧原子、硫原子或基团。 其中 R6 代表甲酰基、C1-4 烷酰基或 C1-4 烷氧羰基； R3 代表 C6-10 碳环芳香基团或含有 5 或 6 成员不饱和杂环的杂环基团，该环含有一个或多个选自 0、N 和 S 的杂原子，并可选择带有一个融合碳环，该碳环或杂环基团可带有一个或多个选自卤素原子的取代基、C1-4烷基、C1-4烷酰基、C1-4烷氧基、C1-4烷氧羰基、C1-4烷硫基、羟基、硝基、氰基和甲酰基、-NR7R8基团（其中R为氢原子或C1-4烷基，RB为氢原子或C1-4烷基、C1-4烷酰基或甲酰基）以及被一个或多个羟基或-NR7R8基团和卤素原子取代的C1-4烷基； n 是数值为 0 或 1 的整数；以及 R4和R5，它们可以相同或不同，各自为氢原子或C1-6烷基）和这类加合物的盐具有移相抑制能力和理想的良好水溶性，可用于抑制异常细胞增殖。
• US4539324A
  申请人：——

  公开号：US4539324A

  公开（公告）日：1985-09-03
• Pyrimidinones as reversible metaphase arresting agents
  作者：T Benneche、P Strande、R Oftebro、K Undheim

  DOI：10.1016/0223-5234(93)90014-6

  日期：1993.1

  5-Halo-N(1)-substituted 2(1H)-pyrimidinones have the ability to cause reversible arrest of mitosis during metaphase, Highly active compounds have a heteroatom (O, S or N) in the beta-position of the N(1)-carbon chain which is further substituted by an aryl group. In vitro data have been provided. It is suggested that reversible metaphase inhibitors can be used as synchronizing agents of cell-cycles by applying them in a sequential manner when a phase-specific cytotoxic drug is used in the treatment of diseases caused by uncontrolled rapidly proliferating cells. The active compounds are prepared from 2-pyrimidinones by alkylation reactions. The key reactants are alpha-chloroalkyl ethers, sulfides and amides; methods for their syntheses have been described.